{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:27:15Z","timestamp":1781659635417,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Spine J"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The identification of gene mutations in the modern medical workup of metastatic spine tumors has become more common but has not been highly utilized in surgical planning. Potential utility of these genetic markers as surrogates for cancer behavior in current prognosis scoring systems and overall survival (OS) remains underexplored in existing literature. This study seeks to investigate the association of frequently identified tumor markers, EGFR, ALK, and PD-L1, in metastatic non-small cell lung cancer (NSCLC) to the spine with Tokuhashi prognosis scoring and OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with NSCLC metastasis to spine were identified through chart review. EGFR, ALK, and PD-L1 wild type vs. mutant type were identified from targeted chemotherapy genetic testing. Multiple linear regression was performed to assess gene profile contributions to Tokuhashi score. Cox Proportional Hazards models were generated for each tumor marker to assess the relationship between each marker and OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 119 patients with NSCLC spine metastasis were identified. We employed a multiple linear regression analysis to investigate the influence of EGFR, ALK, and PD-L1 genotypes on the Tokuhashi score, revealing statistically significant relationships overall (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). Individual genotype contributions include EGFR as a non-significant contributor (<jats:italic>p<\/jats:italic>\u2009=\u20090.269) and ALK and PD-L1 as significant contributors (<jats:italic>p<\/jats:italic>\u2009=\u20090.037 and <jats:italic>p<\/jats:italic>\u2009=\u20090.001 respectively). Overall survival was not significantly associated with tumor marker profiles through Kaplan-Meier analysis (<jats:italic>p<\/jats:italic>\u2009=\u20090.46) or by multivariable analysis (<jats:italic>p<\/jats:italic>\u2009=\u20090.108).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ALK and PD-L1 were significantly associated with Tokuhashi score while EGFR was not. Tumor markers alone were not predictive of OS. These findings indicate that genetic markers found in NSCLC metastases to the spine may demonstrate prognostic value. Therefore, employing standard tumor markers could enhance the identification of appropriate surgical candidates, although they demonstrate limited effectiveness in predicting overall survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00586-024-08447-8","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T16:02:29Z","timestamp":1725292949000},"page":"4346-4352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor markers in non-small cell lung cancer spine metastasis: an assessment of prognosis and overall survival"],"prefix":"10.1007","volume":"33","author":[{"given":"Brian","family":"Foresi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Krishnaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"8447_CR1","unstructured":"Cancer of the Lung and Bronchus - Cancer Stat Facts. (n.d.). SEER. Retrieved October 30 2023, from https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html"},{"issue":"12","key":"8447_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E (2021) Update of incidence, prevalence, survival, and initial treatment in patients with Non-small Cell Lung Cancer in the US. JAMA Oncol 7(12):1824\u20131832","journal-title":"JAMA Oncol"},{"issue":"5","key":"8447_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/21645515.2020.1823779","volume":"17","author":"Y Huang","year":"2021","unstructured":"Huang Y, Zhu L, Guo T et al (2021) Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. Hum Vaccin Immunother 17(5):1278\u20131287","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"8447_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1758834014521110","volume":"6","author":"C D\u2019Antonio","year":"2014","unstructured":"D\u2019Antonio C, Passaro A, Gori B et al (2014) Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 6(3):101\u2013114","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"8447_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jbo.2012.12.004","volume":"2","author":"M Kuchuk","year":"2013","unstructured":"Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P (2013) Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol 2(1):22\u201329. Published 2013 Jan 17. https:\/\/doi.org\/10.1016\/j.jbo.2012.12.004","journal-title":"J Bone Oncol"},{"issue":"17","key":"8447_CR6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2106\/JBJS.N.01124","volume":"97","author":"Y Tang","year":"2015","unstructured":"Tang Y, Qu J, Wu J, Li S, Zhou Y, Xiao J (2015) Metastatic spinal cord Compression from Non-small-cell Lung Cancer treated with surgery and adjuvant therapies: a retrospective analysis of outcomes and prognostic factors in 116 patients. J Bone Joint Surg Am 97(17):1418\u20131425","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"8447_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-12-302","volume":"12","author":"D Rades","year":"2012","unstructured":"Rades D, Douglas S, Veninga T, Schild SE (2012) A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer 12(1):1\u20137","journal-title":"BMC Cancer"},{"issue":"10","key":"8447_CR8","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.spinee.2018.03.011","volume":"18","author":"AK Ahmed","year":"2018","unstructured":"Ahmed AK, Goodwin CR, Heravi A et al (2018) Predicting survival for metastatic spine disease: a comparison of nine scoring systems. Spine J 18(10):1804\u20131814. https:\/\/doi.org\/10.1016\/j.spinee.2018.03.011","journal-title":"Spine J"},{"issue":"12","key":"8447_CR9","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1097\/CORR.0000000000000923","volume":"477","author":"H Murtaza","year":"2019","unstructured":"Murtaza H, Sullivan CW (2019) Classifications in brief: the spinal instability neoplastic score. Clin Orthop Relat Res 477(12):2798\u20132803","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"8447_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/00007632-199011010-00005","volume":"15","author":"Y Tokuhashi","year":"1990","unstructured":"Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S (1990) Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15(11):1110\u20131113","journal-title":"Spine"},{"issue":"19","key":"8447_CR11","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1097\/01.brs.0000180401.06919.a5","volume":"30","author":"Y Tokuhashi","year":"2005","unstructured":"Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J (2005) A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine 30(19):2186\u20132191","journal-title":"Spine"},{"key":"8447_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00586-015-4339-6","volume":"25","author":"C Zoccali","year":"2016","unstructured":"Zoccali C, Skoch J, Walter CM et al (2016) The Tokuhashi score: effectiveness and pitfalls. Eur Spine J 25:673\u2013678. https:\/\/doi.org\/10.1007\/s00586-015-4339-6","journal-title":"Eur Spine J"},{"issue":"Pt 1","key":"8447_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","volume":"52","author":"L Osmani","year":"2018","unstructured":"Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol 52(Pt 1):103\u2013109. https:\/\/doi.org\/10.1016\/j.semcancer.2017.11.019","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"8447_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4132\/jptm.2021.04.29","volume":"55","author":"JH Kim","year":"2021","unstructured":"Kim JH (2021) Prognostic and predictive markers in glioblastoma and ALK overexpression. J Pathol Transl Med 55(3):236","journal-title":"J Pathol Transl Med"},{"key":"8447_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C (2021) Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 27:1345\u20131356. https:\/\/doi.org\/10.1038\/s41591-021-01450-2","journal-title":"Nat Med"},{"key":"8447_CR16","doi-asserted-by":"publisher","unstructured":"Harrell FE (2015) Cox Proportional hazards Regression Model. Regression modeling strategies. Springer Series in Statistics. Springer. https:\/\/doi.org\/10.1007\/978-3-319-19425-7_20","DOI":"10.1007\/978-3-319-19425-7_20"},{"key":"8447_CR17","doi-asserted-by":"publisher","unstructured":"Brouns AJW, van Veelen A, Marijn Veerman GD et al (2023) Incidence of bone metastases and skeletal-related events in patients with EGFR-Mutated NSCLC treated with Osimertinib. JTO Clin Res Rep 4(5). https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100513","DOI":"10.1016\/j.jtocrr.2023.100513"},{"issue":"1","key":"8447_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-09421-7","volume":"22","author":"SS Shimamura","year":"2022","unstructured":"Shimamura SS, Shukuya T, Asao T et al (2022) Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer\u2014is there a tail plateau in the survival curve of these patients? BMC Cancer 22(1):1\u201310","journal-title":"BMC Cancer"},{"issue":"11","key":"8447_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nrc2947","volume":"10","author":"W Pao","year":"2010","unstructured":"Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10(11):760\u2013774. https:\/\/doi.org\/10.1038\/nrc2947","journal-title":"Nat Rev Cancer"},{"key":"8447_CR20","doi-asserted-by":"publisher","unstructured":"Britschgi C, Addeo A, Rechsteiner M et al (2020) Real-world treatment patterns and survival outcome in Advanced anaplastic lymphoma kinase (ALK) rearranged non-small-cell Lung Cancer patients. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.01299","DOI":"10.3389\/fonc.2020.01299"},{"key":"8447_CR21","doi-asserted-by":"publisher","unstructured":"Watanabe S, Hayashi H, Okamoto K et al (2016) Progression-free and overall survival of patients with ALK rearrangement-positive Non-small Cell Lung Cancer treated sequentially with Crizotinib and Alectinib. Clin Lung Cancer 17(6). https:\/\/doi.org\/10.1016\/j.cllc.2016.05.001","DOI":"10.1016\/j.cllc.2016.05.001"},{"key":"8447_CR22","doi-asserted-by":"publisher","unstructured":"Dantoing E, Piton N, Sala\u00fcn M, Thiberville L, Guisier F (2021) Anti-PD1\/PD-L1 immunotherapy for Non-small Cell Lung Cancer with Actionable Oncogenic driver mutations. Int J Mol Sci 22(12). https:\/\/doi.org\/10.3390\/ijms22126288","DOI":"10.3390\/ijms22126288"},{"key":"8447_CR23","unstructured":"Oremek GM, Weis A, Sapoutzis N, Sauer-Eppel H (2003) Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res 23(2A). https:\/\/pubmed.ncbi.nlm.nih.gov\/12820336\/"},{"key":"8447_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8013575","author":"W Szopa","year":"2017","unstructured":"Szopa W, Burley TA, Kramer-Marek G, Kaspera W (2017) Diagnostic and therapeutic biomarkers in Glioblastoma: current status and future perspectives. BioMed Res Int. https:\/\/doi.org\/10.1155\/2017\/8013575","journal-title":"BioMed Res Int"},{"key":"8447_CR25","doi-asserted-by":"publisher","unstructured":"Kelly WJ, Shah NJ, Subramaniam DS (2018) Management of brain metastases in epidermal growth factor receptor mutant non-small-cell Lung Cancer. Front Oncol 8. https:\/\/doi.org\/10.3389\/fonc.2018.00208","DOI":"10.3389\/fonc.2018.00208"},{"key":"8447_CR26","doi-asserted-by":"publisher","unstructured":"Fong WY, Ho CC, Poon WT (2017) Comparison of Direct Sequencing, Real-Time PCR-High Resolution Melt (PCR-HRM) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) Analysis for Genotyping of Common Thiopurine Intolerant Variant Alleles NUDT15 c.415C\u2009>\u2009T and TPMT c.719A\u2009>\u2009G (TPMT*3\u00a0C). Diagnostics 7(2). https:\/\/doi.org\/10.3390\/diagnostics7020027","DOI":"10.3390\/diagnostics7020027"},{"issue":"4","key":"8447_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du X, Shao Y, Qin H, Tai Y, Gao H (2018) ALK-rearrangement in non\u2010small\u2010cell lung cancer (NSCLC). Thorac Cancer 9(4):423","journal-title":"Thorac Cancer"},{"key":"8447_CR28","doi-asserted-by":"publisher","unstructured":"Eichhorn F, Kriegsmann M, Klotz LV et al (2021) Prognostic impact of PD-L1 expression in pN1 NSCLC: a retrospective single-center analysis. Cancers 13(9). https:\/\/doi.org\/10.3390\/cancers13092046","DOI":"10.3390\/cancers13092046"},{"issue":"1","key":"8447_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-020-01696-z","volume":"15","author":"M Vrankar","year":"2020","unstructured":"Vrankar M, Kern I, Stanic K (2020) Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Radiat Oncol 15(1):1\u201312","journal-title":"Radiat Oncol"}],"container-title":["European Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00586-024-08447-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00586-024-08447-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00586-024-08447-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T16:03:55Z","timestamp":1730563435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00586-024-08447-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["8447"],"URL":"https:\/\/doi.org\/10.1007\/s00586-024-08447-8","relation":{},"ISSN":["0940-6719","1432-0932"],"issn-type":[{"value":"0940-6719","type":"print"},{"value":"1432-0932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Portions of the data included in this manuscript were presented at the Congress of Neurological Surgeons national meeting 2023 as a poster presentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}},{"value":"The authors have no disclosures and have no financial interests in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}